Rallybio Corporation (Nasdaq: RLYB) (“Rallybio”) and Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, announce that they have entered into a definitive agreement pursuant to which Rallybio will acquire Avenzo through a merger transaction (the “Merger”). Upon completion of the Merger, the combined company is expected to operate under the name Avenzo Therapeutics, Inc. and is expected to trade on Nasdaq under the ticker symbol “AVZO”. In connection with the Merger, Avenzo entered into subscription agreements for a concurrent oversubscribed private placement financing of $215 million in gross proceeds (the “Financing” and, together with the Merger, the “Transaction”).
Read the full article: Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215M Concurrent Private Placement //
Source: https://www.businesswire.com/news/home/20260531328050/en/Rallybio-Corporation-and-Avenzo-Therapeutics-Announce-Merger-Agreement-to-Advance-Next-Generation-Oncology-Therapies-and-%24215-Million-Concurrent-Private-Placement